Labial fusion is defined as either partial or complete adherence of the labia minora. It is also known as vulvar fusion, labial adhesion, labial agglutination or synechia of the vulva. This condition is common in pre-pubertal girls when estrogen levels are low and commonly resolves spontaneously post-puberty. This condition is usually asymptomatic and can be treated with topical application of estrogen or betamethasone cream or by manual or surgical separation of adhesions. We present a case of labial fusion in post pubertal girl which was managed surgically.

No abstract

Aims & Objectives: To determine the effectiveness and safety of IV Iron sucrose therapy in antenatal women with moderate to severe Iron deficiency anaemia. Methodology: It is a retrospective study with secondary data analysis. We have analyzed the data collected from January 2019 to December 2019 at the Nootan general hospital, Visnagar, Gujarat, India. Analysis of antenatal  women with moderate to severe anaemia (Hb 6 to 8gm%) in the second trimester  and early third trimester(20 to 34weeks of gestation) are done during their  routine antenatal care  who were prescribed Intravenous Iron sucrose in a standard-dose of 1000 mg given as 200 mg on alternate days after confirming the iron deficiency anaemia. Effectiveness of the therapy has been studied by comparing the Hb level at the point baseline where start of the treatment and 4 week or more after the last treatment was given (endline). The safety profile of the therapy has been assessed by noticing any adverse drug reaction after starting the infusion. Results: Mean increase in Hb in cases of moderate & severe anaemia was 3.69 g/dl (1.19) and 3.91 (1.25) g/dl respectively. Overall rise of Haemoglobin was 3.79 g/dl (1.1)(95% CL: 3.35, 4.23).  Calculated p value in our study is < 0.001 which is statistically significant. Conclusion: The mean rise in Haemoglobin level in our study was 3.79 g/dL when 1000 mg of Intra venous iron sucrose was given to antenatal women with moderate as well as severe anaemia is concerned. The magnitude of the anaemia difference is directly proportional rise of haemoglobin level. The amount of haemoglobin rise is seen more in severe anaemic antenatal patients compared with moderate antenatal patients. We recommend that Intravenous iron sucrose therapy should be included as second choice for severely anaemic pregnant women where situation is not supportive for blood transfusion or patient is noncompliant.

Anaemia during pregnancy is allied with maternal and foetal complications like increased risk of intrauterine growth retardation, prematurity, low birth weight, and maternal and infant mortality. The agent iron isomaltose 1000 (Fur-IV) combines iron and isomaltose 1000 for slow, controlled release to reduce the risk of free iron toxicity and provide flexibility and convenience for high dose administration. Iron isomaltoside has been shown to be effective in the treatment of IDA in many treatment groups compared to intravenous iron sucrose and FCM. : It is a prospective interventional study which is conducted to observe an increase in hemoglobin levels in obstetric and gynecological department patients suffering from IDA in whom oral iron preparation was ineffective or in case of clinical need to supply iron rapidly via single infusion of iron isomaltoside 1000. Each patient in the study received 500 mg single intravenous infusion. After this, patient was followed up and haemogram was repeated after 15 and 30 days of infusion while investigation for serum ferritin and serum iron was repeated after 30 days. Average Hb concentration in increased by 30.86% to 9.88 g/dL after 30 days of infusion. There is statistically significant difference between baseline values and post infusion 30 days values for serum ferritin and serum iron (p-value &#60;0.0001 for both).IV iron isomaltoside administration was well tolerated in patients with gynecological IDA who were intolerant or unresponsive to oral iron therapy or who required rapid iron administration.